)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Elite Pharmaceuticals
Elite Pharmaceuticals (ELTP) investor relations material
Elite Pharmaceuticals Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary14 Aug, 2026
Executive summary
Q1 FY2027 revenue was $32.4M, down 19.5% year over year from a record prior-year quarter; operating income was $7.5M, down 65%.
Net income attributable to common shareholders was $5.9M.
Product volumes and market shares advanced while pricing stabilized; pipeline investment and launches continued.
Financial highlights
Revenue was $32.4M, down $7.9M year over year; gross profit fell 50% to $13.5M and gross margin declined to 42% from 68%.
Operating income was $7.5M, down 65% from $21.7M, mainly reflecting lower margins on generic Vyvanse® sales.
Net income was $5.9M versus a $5.9M prior-year net loss, aided by a favorable change in derivative warrant fair value.
Operating cash flow was $10.1M vs. $14.8M year over year; cash and restricted cash totaled $39.4M at quarter-end.
R&D expense was $2.0M vs. $1.7M year over year.
Outlook and guidance
Management expects product development and pipeline launches to support future revenue and profit growth; no quantified near-term target was stated.
Methadone launched in April and ropinirole ER in July; both are expected to contribute to future growth.
Management expects Nasdaq uplisting as a standalone path or alongside an acquisition, with completion or near-finalization estimated by February 2027.
Oxycodone ER launch by August 2027 depends on resolving an FDA anti-abuse issue; an undisclosed anticoagulant may launch in 2028, subject to negotiations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elite Pharmaceuticals
- Q2 revenue rose 10.4%; H1 earnings benefited from warrant remeasurement as margins compressed.ELTP
Q2 2027 - Revenue up 77% and operating income up 151% year-over-year, fueled by new product launches.ELTPQ4 2026
- Revenue and profit more than doubled, driven by new generics and strong market share.ELTPQ3 2026
- Revenue up 92% to $36.3M, net income $13.7M, driven by new launches and strong cash flow.ELTPQ2 2026
- Revenue and profit surged, but a $22.1M warrant expense led to a net loss.ELTPQ1 2026
- Revenue up 33% to $18.9M, but non-cash warrant expense drove a net loss.ELTPQ2 2025
- Revenue up 109% to $18.8M; operating income and profit surged despite non-cash warrant expense.ELTPQ1 2025
- Revenue up 65% to $56.6M, operating profit $10.8M, targeting $70M next year.ELTPQ4 2024
- Nine-month revenue up 35% to $52M, but Q3 profit fell on shipment delays and warrant revaluation.ELTPQ3 2025
Next Elite Pharmaceuticals earnings date
Q2 202713 Nov, 2026
Elite Pharmaceuticals
Next Elite Pharmaceuticals earnings date
Q2 202713 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Elite Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, manufacture, and distribution of niche generic and oral controlled-release medications. The company primarily targets the opioid abuse-deterrent and extended-release segments of the pharmaceutical market, offering treatments across a variety of therapeutic areas. Elite Pharmaceuticals specializes in developing formulations that address controlled substance regulations and the potential for abuse. The company’s business model includes both the commercialization of its own products and contract manufacturing services for third-party pharmaceutical companies. The company is headquartered in Northvale, New Jersey, and its shares are listed on the OTCQB.